Navigation Links
Novo Nordisk Inc. Appoints Eddie Li as Vice President, Regulatory Affairs

PRINCETON, N.J., Sept. 7, 2011 /PRNewswire/ -- Novo Nordisk Inc. announced today that Dr. Eddie Li, has been appointed to join the diabetes leader as Vice President, Regulatory Affairs starting September 12.

Reporting to Anne Philips, M.D., Corporate Vice President, Clinical Development, Medical and Regulatory Affairs for North America, Dr. Li brings over 20 years of industry, public sector, and academic experience in the field of regulatory affairs and safety.  He'll be leading Novo Nordisk's U.S. regulatory team, and maintain relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the U.S. Food and Drug Administration's (FDA) review and approval process.

"Eddie has worked within the FDA and other pharmaceutical peers so he brings a wealth of experience to Novo Nordisk.  He comes to us at a critical time in our company as our portfolio continues to grow," said Anne Phillips, M.D., corporate vice president, Clinical, Medical and Regulatory Affairs.  "The regulatory environment is becoming increasingly complex, and Eddie's background suits our needs to have a senior leader as our main point of contact with the FDA."

Originally trained in medicine and toxicology, Dr. Li has an extensive background in the pharmaceutical industry, joining Novo Nordisk from Sanofi, where he most recently was global head of regulatory affairs for one of its largest therapy areas.  He has also worked at Johnson & Johnson and AstraZeneca.  He also served as a staff reviewer at the FDA.

Eddie studied in the Shanghai First Medical College.  He subsequently completed his Ph.D. in Toxicology at the University of Arkansas for Medical Sciences, and also studied in an M.B.A. program at the University of Delaware.

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care.  The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy.  For more information, visit

SOURCE Novo Nordisk Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs
2. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters
3. Novo Nordisk A/S: PharmaVitae Profile
4. Video from Novo Nordisk A/S available on Novo Nordisk Receives Approval for Victoza in China
5. Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval
6. Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders
7. Novo Nordisk Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case
8. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
9. Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
10. Novo Nordisk and Chip Ganassi Racing Team Up for 2011 IZOD IndyCar Series
11. Novo Nordisk and Entertainment Industries Council Work Together to Improve Public Education and Awareness about Diabetes Epidemic
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):